The American Academy of Child and Adolescent Psychiatry and the American Academy of Pediatrics have developed practice parameters describing the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) based on the current scientific evidence and the clinical consensus of ADHD experts in the field.
American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameters
Practice Parameters for the Assessment and Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Journal of the American Academy of Child and Adolescent Psychiatry, 46:7, 894-921, 2007
These practice parameters focus on the assessment, diagnostic, and treatment planning process, emphasizing a developmental perspective. Recommendations are based on extensive review of the scientific literature and clinical consensus among experts in the subject. Assessment includes clinical interviews with the child and parents and standardized rating scales from parent and teachers. Testing of intelligence and academic achievement is usually required. Comorbidity is common.
The cornerstones of treatment are support and education of parents, appropriate school placement, and psychopharmacology. The primary medications are psychostimulants, but antidepressants and alpha-adrenergic agonists are used in special circumstances. Other treatments such as behavior modification, school consultation, family therapy, and group therapy address remaining symptoms.
Practice parameter on the use of psychotropic medication in children and adolescents
American Academy of Child & Adolescent Psychiatry
This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, and mixed salts amphetamine.
AAP Clinical Practice Guidelines
Diagnosis, Evaluation and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents
American Academy of Pediatrics
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management
Pediatrics, October 16, 2011
This clinical practice guideline updates and brings together into one document two separate guidelines issued in 2000 (for evaluation and diagnosis) and in 2001 (for treatment).
The Guideline's six key action statements are summarized as follows:
AAP developed these guidelines in collaboration with several professional organizations, including the American Academy of Child and Adolescent Psychiatry, the Child Neurology Society, the Society for Pediatric Psychology, the National Association of School Psychologists, the Society for Developmental and Behavioral Pediatrics, and the American Academy of Family Physicians. CHADD was the only family-based organization also to participate in the development of these guidelines, represented on the team by former CHADD President Beth Kaplanek.